NasdaqGS:SNDX

Stock Analysis Report

Executive Summary

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer.

Snowflake

Fundamentals

Flawless balance sheet with high growth potential.

Share Price & News

How has Syndax Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.7%

NasdaqGS:SNDX

0.6%

US Biotechs

1.3%

US Market


1 Year Return

26.8%

NasdaqGS:SNDX

-10.3%

US Biotechs

2.0%

US Market

SNDX outperformed the Biotechs industry which returned -10.8% over the past year.

SNDX outperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

SNDXIndustryMarket
7 Day-0.7%0.6%1.3%
30 Day-14.4%-1.2%3.9%
90 Day-3.0%-0.1%3.4%
1 Year26.8%26.8%-9.5%-10.3%4.2%2.0%
3 Year-36.5%-36.5%7.1%3.5%47.2%37.6%
5 Yearn/a3.3%-1.7%60.5%42.9%

Price Volatility Vs. Market

How volatile is Syndax Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Syndax Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Syndax Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).

Syndax Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Syndax Pharmaceuticals is loss making, we can't compare its value to the US Biotechs industry average.

Syndax Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Syndax Pharmaceuticals, we can't assess if its growth is good value.


Price Based on Value of Assets

Syndax Pharmaceuticals is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Syndax Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

26.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Syndax Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.

Syndax Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.

Syndax Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.

Syndax Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.

Syndax Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Syndax Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has Syndax Pharmaceuticals performed over the past 5 years?

-4.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Syndax Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Syndax Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Syndax Pharmaceuticals's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Syndax Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Syndax Pharmaceuticals has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Syndax Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Syndax Pharmaceuticals's financial position?


Financial Position Analysis

Syndax Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Syndax Pharmaceuticals's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Syndax Pharmaceuticals has no debt.

Syndax Pharmaceuticals has no debt compared to 5 years ago when it was 2.5%.


Balance Sheet

Low level of unsold assets.

Syndax Pharmaceuticals has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Syndax Pharmaceuticals has sufficient cash runway for 1.3 years based on current free cash flow.

Syndax Pharmaceuticals has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 29.3% each year.


Next Steps

Dividend

What is Syndax Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Syndax Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Syndax Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Syndax Pharmaceuticals has not reported any payouts.

Unable to verify if Syndax Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Syndax Pharmaceuticals has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Syndax Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Syndax Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

4.3yrs

Average management tenure


CEO

Briggs Morrison (59yo)

4.3yrs

Tenure

US$2,080,513

Compensation

Dr. Briggs W. Morrison, M.D. serves as the Executive Partner MPM Capital. He joined MPM in 2015. He is the Chairman of Scientific Advisory Board at Cerenis Therapeutics Holding SA since May 2018. Dr. Morri ...


CEO Compensation Analysis

Briggs's remuneration is higher than average for companies of similar size in United States of America.

Briggs's compensation has increased whilst company is loss making.


Management Age and Tenure

4.3yrs

Average Tenure

60.5yo

Average Age

The tenure for the Syndax Pharmaceuticals management team is about average.


Board Age and Tenure

3.2yrs

Average Tenure

57.5yo

Average Age

The tenure for the Syndax Pharmaceuticals board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$152,24313 May 19
Briggs Morrison
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares20,400
Max PriceUS$7.56
BuyUS$5,47525 Mar 19
Michael Meyers
EntityIndividual
Role
Senior Key Executive
Chief Medical Officer
Shares1,112
Max PriceUS$4.93
BuyUS$95807 Nov 18
Michael Meyers
EntityIndividual
Role
Senior Key Executive
Chief Medical Officer
Shares200
Max PriceUS$4.79

Ownership Breakdown


Management Team

  • Rick Shea (67yo)

    CFO & Treasurer

    • Tenure: 2.6yrs
    • Compensation: US$13.00k
  • Ed Sausville

    • Tenure: 0yrs
  • Ronald Evans

    Co-Founder

    • Tenure: 3.2yrs
  • Michael Metzger (48yo)

    President

    • Tenure: 0.2yrs
    • Compensation: US$1.52m
  • Rich Heyman (62yo)

    Co-Founder

    • Tenure: 0yrs
  • Peter Ordentlich (50yo)

    Co-Founder & Chief Scientific Officer

    • Tenure: 13.9yrs
  • Michael Downes

    Co-Founder

    • Tenure: 0yrs
  • Briggs Morrison (59yo)

    CEO & Director

    • Tenure: 4.3yrs
    • Compensation: US$2.08m
  • Luke Albrecht

    General Counsel & Corporate Secretary

    • Tenure: 0yrs
  • Michael Meyers (68yo)

    Chief Medical Officer

    • Tenure: 4.1yrs
    • Compensation: US$1.05m

Board Members

  • Jay Lichter (57yo)

    Observer

    • Tenure: 0yrs
  • Keith Katkin (48yo)

    Director

    • Tenure: 2.5yrs
    • Compensation: US$209.91k
  • Pierre Legault (58yo)

    Director

    • Tenure: 2.7yrs
    • Compensation: US$223.16k
  • Dennis Podlesak (61yo)

    Chairman

    • Tenure: 10.8yrs
    • Compensation: US$245.16k
  • George Sledge (67yo)

    Member of Scientific Advisory Board

    • Tenure: 2.4yrs
    • Compensation: US$23.05k
  • Ronald Evans

    Co-Founder

    • Tenure: 3.2yrs
  • Michael Metzger (48yo)

    President

    • Tenure: 0.2yrs
    • Compensation: US$1.52m
  • Fabrice Egros (56yo)

    Director

    • Tenure: 6yrs
    • Compensation: US$199.66k
  • Briggs Morrison (59yo)

    CEO & Director

    • Tenure: 4.3yrs
    • Compensation: US$2.08m
  • Julie Brahmer

    Member of Scientific Advisory Board

    • Tenure: 3.8yrs

Company Information

Syndax Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Syndax Pharmaceuticals, Inc.
  • Ticker: SNDX
  • Exchange: NasdaqGS
  • Founded: 2005
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$237.718m
  • Shares outstanding: 27.14m
  • Website: https://www.syndax.com

Number of Employees


Location

  • Syndax Pharmaceuticals, Inc.
  • 35 Gatehouse Drive
  • Building D
  • Waltham
  • Massachusetts
  • 2451
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
1T3DB (Deutsche Boerse AG)YesCommon StockDEEURMar 2016
SNDXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMar 2016

Biography

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company’s lead product candidates include entinostat, which is in Phase III cli ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/16 00:21
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.